Abstract
The effect of the valpromide isomer valnoctamide (VCD, 200 mg three times daily for 8 days), an over-the-counter tranquillizer, on the elimination kinetics of a single oral dose of carbamazepine-10, 11-epoxide (CBZ-E, 100 mg) was investigated in healthy subjects. During VCD treatment, the half-life of CBZ-E was prolonged significantly compared with control (19.7 +/- 6.7 h vs 6.9 +/- 2.0 h, means +/- s.d., P less than 0.01), and its oral clearance decreased four-fold (from 109.6 +/- 30.7 to 28.8 +/- 11.1 ml h-1 kg-1, P less than 0.01). These findings indicate that VCM, like valpromide, strongly inhibits epoxide hydrolase in vivo.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bertilsson L., Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet. 1986 May-Jun;11(3):177–198. doi: 10.2165/00003088-198611030-00001. [DOI] [PubMed] [Google Scholar]
- Bialer M., Haj-Yehia A., Barzaghi N., Pisani F., Perucca E. Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. Eur J Clin Pharmacol. 1990;38(3):289–291. doi: 10.1007/BF00315032. [DOI] [PubMed] [Google Scholar]
- Bialer M., Rubinstein A., Raz I., Abramsky O. Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. Eur J Clin Pharmacol. 1984;27(4):501–503. doi: 10.1007/BF00549603. [DOI] [PubMed] [Google Scholar]
- Haj-Yehia A., Bialer M. Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity. J Pharm Sci. 1990 Aug;79(8):719–724. doi: 10.1002/jps.2600790814. [DOI] [PubMed] [Google Scholar]
- Kerr B. M., Rettie A. E., Eddy A. C., Loiseau P., Guyot M., Wilensky A. J., Levy R. H. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation. Clin Pharmacol Ther. 1989 Jul;46(1):82–93. doi: 10.1038/clpt.1989.110. [DOI] [PubMed] [Google Scholar]
- Meijer J. W., Binnie C. D., Debets R. M., van Parys J. A., de Beer-Pawlikowski N. K. Possible hazard of valpromide-carbamazepine combination therapy in epilepsy. Lancet. 1984 Apr 7;1(8380):802–802. doi: 10.1016/s0140-6736(84)91325-4. [DOI] [PubMed] [Google Scholar]
- Pacifici G. M., Tomson T., Bertilsson L., Rane A. Valpromide/carbamazepine and risk of teratogenicity. Lancet. 1985 Feb 16;1(8425):397–398. doi: 10.1016/s0140-6736(85)91417-5. [DOI] [PubMed] [Google Scholar]
- Pisani F., Caputo M., Fazio A., Oteri G., Russo M., Spina E., Perucca E., Bertilsson L. Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. Epilepsia. 1990 May-Jun;31(3):339–342. doi: 10.1111/j.1528-1157.1990.tb05385.x. [DOI] [PubMed] [Google Scholar]
- Pisani F., Fazio A., Oteri G., Ruello C., Gitto C., Russo F., Perucca E. Sodium valproate and valpromide: differential interactions with carbamazepine in epileptic patients. Epilepsia. 1986 Sep-Oct;27(5):548–552. doi: 10.1111/j.1528-1157.1986.tb03582.x. [DOI] [PubMed] [Google Scholar]
- Pisani F., Fazio A., Oteri G., Spina E., Perucca E., Bertilsson L. Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide. Br J Clin Pharmacol. 1988 May;25(5):611–613. doi: 10.1111/j.1365-2125.1988.tb03354.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Robbins D. K., Wedlund P. J., Kuhn R., Baumann R. J., Levy R. H., Chang S. L. Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine. Br J Clin Pharmacol. 1990 Jun;29(6):759–762. doi: 10.1111/j.1365-2125.1990.tb03698.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- STEPANSKY W. A clinical study in the use of valmethamide, an anxiety-reducing drug. Curr Ther Res Clin Exp. 1960 May;2:144–147. [PubMed] [Google Scholar]